847499-95-0

Basic information

• Product Name: 1-(2-AMINO-ETHYL)-PIPERIDIN-3-OL
• Synonyms: 1-(2-aminoethyl)piperidin-3-ol(SALTDATA: FREE);1-(2-AMinoethyl)-3-piperidinol
• CAS NO: 847499-95-0
• Molecular Formula: C₇H₁₆N₂O
• Molecular Weight: 144.22
• Mol File: 847499-95-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 250.4°C at 760 mmHg
• Flash Point: 105.3°C
• Appearance: /
• Density: 1.062g/cm³
• Vapor Pressure: 0.00344mmHg at 25°C
• Refractive Index: 1.517
• CAS DataBase Reference: 1-(2-AMINO-ETHYL)-PIPERIDIN-3-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-AMINO-ETHYL)-PIPERIDIN-3-OL(847499-95-0)
• EPA Substance Registry System: 1-(2-AMINO-ETHYL)-PIPERIDIN-3-OL(847499-95-0)

Safety Data

• Hazardous Substances Data: 847499-95-0(Hazardous Substances Data)

Usage

General Description

1-(2-AMINO-ETHYL)-PIPERIDIN-3-OL is a chemical compound with the molecular formula C8H18N2O. It is also known as N-(2-hydroxyethyl)piperidine and is a member of the piperidine class of compounds. This chemical is a viscous liquid at room temperature and is commonly used in the pharmaceutical industry as a precursor for the synthesis of various drugs. It possesses a piperidine ring structure and a hydroxyethyl group, making it suitable for involvement in the formation of biologically active compounds. Its properties and structure also make it a potentially valuable intermediate in the development of new pharmaceuticals and research in the field of medicinal chemistry.

InChI:InChI=1/C7H16N2O/c8-3-5-9-4-1-2-7(10)6-9/h7,10H,1-6,8H2

Upstream product

• 6859-99-0 3-hydroxypiperazine 
• 857637-25-3 [2-(3-hydroxy-piperidin-1-yl)-ethyl]-carbamic acid tert-butyl ester 
• 857636-97-6 2-(3-hydroxypiperidin-1-yl)acetonitrile 

Downstream Products

• 857637-25-3 [2-(3-hydroxy-piperidin-1-yl)-ethyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

SMALL MOLECULES INHIBITING TDP-43 ACTIVITY AND USES THEREOF

The present invention relates to the field of medical pharmacology. In particular, the present invention relates to pharmaceutical agents that serve as inhibitors of the activity of TDP-43. The invention further relates to methods of treatment and / or alleviation of symptoms related to pathological conditions associated with the activity of TDP-43 (for example, neurodevelopmental disorders), comprising the administration to a subject (for example, a human patient) of a composition comprising one or more pharmaceutical agents serving as inhibitors of the activity of TDP-43.

Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells

A novel series of 1,4-disubstituted aminoanthraquinones were prepared by ipso-displacement of 1,4-difluoro-5,8-dihydroxyanthraquinones by hydroxylated piperidinyl- or pyrrolidinylalkyl-amino side chains. One aminoanthraquinone (13) was further derivatized to a chloropropyl-amino analogue by treatment with triphenylphosphine-carbon tetrachloride. The compounds were evaluated in the A2780 ovarian cancer cell line and its cisplatin-resistant variants (A2780/cp70 and A2780/MCP1). The novel anthraquinones were shown to possess up to 5-fold increased potency against the cisplatin-resistant cells compared to the wild-type cells. Growth curve analysis of the hydroxyethylaminoanthraquinone 8 in the osteosarcoma cell line U-2 OS showed that the cell cycle is not frozen, rather there is a late cell cycle arrest consistent with the action of a DNA-damaging topoisomerase II inhibitor. Accumulative apoptotic events, using time lapse photography, indicate that 8 is capable of fully engaging cell cycle arrest pathways in G2 in the absence of early apoptotic commitment. 8 and its chloropropyl analogue 13 retained significant activity against human A2780/cp70 xenografted tumors in mice.

Design and synthesis of a DNA-crosslinking azinomycin analogue

The azinomycins are potent antitumour antibiotics that are able to crosslink DNA, but are relatively unstable and unlikely to progress as therapeutic candidates. A prototype analogue 4 with more clinical potential has been designed and synthesised and inc